Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Stem Cell Therapy Alofisel Wins European Approval: Takeda
March 27, 2018
- JCR Shooting for Big Chunk of 900 Billion Yen Global Lysosome Storage Disease Market with J-Brain Cargo
March 27, 2018
- Mitsubishi Tanabe Aims to Attain Efficiency in Clinical Trials through Full-Fledged Use of Hitachi’s AI Technology
March 27, 2018
- Japan Approves 1st Herceptin Biosimilar for Gastric Cancer
March 26, 2018
- Shionogi Partners with CARB-X to Fight CRE Superbug
March 23, 2018
- Thomas-Peter Hausner Named Next President of Bayer Holdings Japan
March 23, 2018
- Lilly Japan Sales Up 7% in 2017, Upbeat Biz Fueled by Global Simultaneous Development
March 23, 2018
- Eldecalcitol NDA Accepted in China: Chugai
March 23, 2018
- J-TEC’s Cell Sheet JACE Filed for Epidermolysis Bullosa
March 23, 2018
- EA Pharma, Irish Cosmo Technologies Hook Up on Colonoscopy Products
March 23, 2018
- Single Generic Pricing Rule Will Accelerate Unreasonable Price Raises: Sawai Chief
March 22, 2018
- Takeda Global Headquarters Completed
March 22, 2018
- Mircera 12.5μg Version Approved in Japan: Chugai
March 22, 2018
- Life Science Institute to Launch Cell Processing Center for Muse Cells, Aiming to Commence Operations in Jan. 2019
March 22, 2018
- Toho Forms Capital Alliance with Tokyo Upstart HekaBio
March 20, 2018
- Hitachi Chemical Wins Clinical Regenerative Medicine Manufacturing Deal from Daiichi Sankyo
March 20, 2018
- Opdivo Picks Up HCC Nod in Taiwan
March 20, 2018
- Top Court Slaps Down Debiopharm’s Appeal over Elplat Patent
March 20, 2018
- Xtandi Gets FDA Priority Review Status for Add’l CRPC Indication
March 20, 2018
- IBL, Astellas Wind Up Human Fibrinogen Collaboration
March 20, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…